Skip to main content
Premium Trial:

Request an Annual Quote

Thermo Fisher Scientific to Market, Sell Synthego Synthetic Guide RNAs

NEW YORK (GenomeWeb) – Synthego said today that Thermo Fisher Scientific will market and sell its synthetic guide RNA products under a Thermo Fisher brand.

Synthego will manufacture synthetic guide RNAs for Thermo Fisher, including a synthetic crRNA:tracrRNA, a synthetic single guide RNA, and a chemically modified sgRNA. Thermo Fisher will sell these products, which may differ from Synthego's own products in configuration and design, under the Invitrogen TrueGuide brand.

"With Thermo Fisher's reputation and extensive market reach, this partnership will make high-quality synthetic guide RNA technologies for CRISPR genome engineering readily accessible to all scientists worldwide," Synthego CEO Paul Dabrowski said in a statement.

"Synthego's manufacturing capabilities for synthetic guide RNAs are ideal to produce Thermo Fisher's TrueGuide synthetic gRNAs," added Helge Bastian, Thermo Fisher's vice president and general manager of synthetic biology. "With the addition of TrueGuide synthetic gRNAs, Invitrogen's TrueEdit portfolio now provides end-to-end solutions for researchers' genome editing applications."

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.